Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1968 1
1969 2
1970 1
1971 2
1972 3
1975 2
1976 3
1977 2
1978 9
1979 8
1980 11
1981 7
1982 16
1983 28
1984 35
1985 34
1986 37
1987 30
1988 53
1989 60
1990 52
1991 53
1992 72
1993 78
1994 100
1995 111
1996 107
1997 72
1998 95
1999 92
2000 73
2001 78
2002 71
2003 81
2004 73
2005 69
2006 70
2007 63
2008 61
2009 34
2010 39
2011 56
2012 57
2013 59
2014 42
2015 44
2016 37
2017 35
2018 32
2019 34
2020 33
2021 27
2022 37
2023 38
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

2,290 results

Results by year

Filters applied: . Clear all
Page 1
Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N; BC2001 Investigators. Hall E, et al. Eur Urol. 2022 Sep;82(3):273-279. doi: 10.1016/j.eururo.2022.04.017. Epub 2022 May 14. Eur Urol. 2022. PMID: 35577644 Free article. Clinical Trial.
BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy (James ND, Hussain SA, Hall E, et al. Radiothera …
BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improv …
Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 5 Years of Follow-up.
Gedde SJ, Feuer WJ, Lim KS, Barton K, Goyal S, Ahmed II, Brandt JD; Primary Tube Versus Trabeculectomy Study Group. Gedde SJ, et al. Ophthalmology. 2022 Dec;129(12):1344-1356. doi: 10.1016/j.ophtha.2022.07.003. Epub 2022 Jul 12. Ophthalmology. 2022. PMID: 35835337 Free PMC article. Clinical Trial.
METHODS: Patients were enrolled at 16 clinical centers and randomly assigned to treatment with a tube shunt (350-mm(2) Baerveldt glaucoma implant) or trabeculectomy with mitomycin C (MMC) (0.4 mg/ml for 2 minutes). MAIN OUTCOME MEASURES: The primary outcome measure was the …
METHODS: Patients were enrolled at 16 clinical centers and randomly assigned to treatment with a tube shunt (350-mm(2) Baerveldt glaucoma im …
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Kleinmann N, et al. Lancet Oncol. 2020 Jun;21(6):776-785. doi: 10.1016/S1470-2045(20)30147-9. Epub 2020 Apr 29. Lancet Oncol. 2020. PMID: 32631491 Clinical Trial.
We aimed to assess the safety and activity of a non-surgical treatment using instillation of UGN-101, a mitomycin-containing reverse thermal gel. METHODS: In this open-label, single-arm, phase 3 trial, participants were recruited from 24 academic sites in the USA and Israe …
We aimed to assess the safety and activity of a non-surgical treatment using instillation of UGN-101, a mitomycin-containing reverse …
A comparative clinical trial of mitomycin C and cyclosporin A in trabeculectomy.
Turaçli E, Gündüz K, Aktan G, Tamer C. Turaçli E, et al. Eur J Ophthalmol. 1996 Oct-Dec;6(4):398-401. doi: 10.1177/112067219600600410. Eur J Ophthalmol. 1996. PMID: 8997582 Clinical Trial.

According to these criteria, IOP was under control in 90% of the mitomycin C treated eyes, 85.7% of cyclosporin A treated eyes and 71.4% of the control eyes. Postoperatively there was a significant decrease in IOP (p < 0.01) and in the number of medications need to cont

According to these criteria, IOP was under control in 90% of the mitomycin C treated eyes, 85.7% of cyclosporin A treated eyes and 71 …
A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.
Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. Inman BA, et al. Int J Hyperthermia. 2014 May;30(3):171-5. doi: 10.3109/02656736.2014.882021. Epub 2014 Feb 3. Int J Hyperthermia. 2014. PMID: 24490762 Free PMC article. Clinical Trial.
PURPOSE: This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mitomycin C (MMC) as a novel therapy for non-muscle-invasive bladder cancer (NMIBC). ...
PURPOSE: This paper aims to evaluate the safety and heating efficiency of external deep pelvic hyperthermia combined with intravesical mi
Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial.
Miyata Y, Tsurusaki T, Hayashida Y, Imasato Y, Takehara K, Aoki D, Nishikido M, Watanabe J, Mitsunari K, Matsuo T, Ohba K, Taniguchi K, Sakai H; Nagasaki University Urological Oncology Research Group. Miyata Y, et al. BJU Int. 2022 Apr;129(4):534-541. doi: 10.1111/bju.15571. Epub 2021 Aug 24. BJU Int. 2022. PMID: 34383381 Free PMC article. Clinical Trial.
OBJECTIVES: To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-muscle-invasive bladder cancer (NMIBC) receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy. ...
OBJECTIVES: To compare the urinary pH, recurrence-free survival (RFS), and safety of adjuvant intravesical therapy in patients with non-musc …
Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer.
Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, Rockwell S, Sartorelli AC, Fischer JJ. Weissberg JB, et al. Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):3-9. doi: 10.1016/0360-3016(89)90362-3. Int J Radiat Oncol Biol Phys. 1989. PMID: 2501243 Clinical Trial.
Actuarial disease-free survival at 5 years was 49% in the radiation therapy group and 75% in the radiation therapy plus mitomycin C group, p less than 0.07. Local recurrence-free survival was 66% in the radiation therapy group and 87% in the radiation therapy plus mitom
Actuarial disease-free survival at 5 years was 49% in the radiation therapy group and 75% in the radiation therapy plus mitomycin C g …
Outcomes of Glaucoma Reoperations in the Primary Tube Versus Trabeculectomy Study.
Coulon SJ, Vanner EA, Gedde SJ; Primary Tube Versus Trabeculectomy Study Group. Coulon SJ, et al. Ophthalmol Glaucoma. 2023 Jul-Aug;6(4):422-431. doi: 10.1016/j.ogla.2023.02.003. Epub 2023 Feb 22. Ophthalmol Glaucoma. 2023. PMID: 36828230 Free PMC article. Clinical Trial.
METHODS: Randomization assigned 125 patients to placement of a tube shunt (350-mm(2) Baerveldt glaucoma implant) and 117 patients to trabeculectomy with mitomycin C (MMC, 0.4 mg/ml for 2 minutes). Data were analyzed from patients who underwent additional glaucoma surgery. …
METHODS: Randomization assigned 125 patients to placement of a tube shunt (350-mm(2) Baerveldt glaucoma implant) and 117 patients to trabecu …
Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Gabizon AA, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P. Gabizon AA, et al. Invest New Drugs. 2020 Oct;38(5):1411-1420. doi: 10.1007/s10637-020-00897-3. Epub 2020 Jan 18. Invest New Drugs. 2020. PMID: 31955309 Clinical Trial.
Background Pegylated liposomal (PL) mitomycin-c lipidic prodrug MLP) may be a useful agent in patients with metastatic colo-rectal carcinoma (CRC). ...
Background Pegylated liposomal (PL) mitomycin-c lipidic prodrug MLP) may be a useful agent in patients with metastatic colo-rectal ca …
Laser-assisted deep sclerectomy.
Vergés C, Llevat E, Bardavio J. Vergés C, et al. J Cataract Refract Surg. 2002 May;28(5):758-65. doi: 10.1016/s0886-3350(01)01257-3. J Cataract Refract Surg. 2002. PMID: 11978452 Clinical Trial.
The mean duration of treatment was 18.3 months +/- 9.4 (SD). After mitomycin-C 0.02% was administered for 2 minutes, a superficial 4.0 mm x 4.0 mm scleral flap was created and a deep 3.0 mm x 3.0 mm scleral ablation was performed with the Er:YAG laser. ...
The mean duration of treatment was 18.3 months +/- 9.4 (SD). After mitomycin-C 0.02% was administered for 2 minutes, a superficial 4. …
2,290 results